Pharming Group (NASDAQ:PHAR) Shares Gap Down - Here's Why

Key Points

• Pharming Group's shares gapped down, opening at $13.54 after closing at $14.80, representing a decline of 9.3%.
• The company reported $0.06 earnings per share for the last quarter, exceeding analyst expectations of a ($0.10) loss, with revenues of $93.20 million.
• A hedge fund recently acquired a new stake in Pharming Group, purchasing 2,979 shares valued at approximately $32,000.

Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Get Free Report)'s share price gapped down prior to trading on Friday . The stock had previously closed at $14.80, but opened at $13.54. Pharming Group shares last traded at $13.36, with a volume of 21,011 shares traded.

Pharming Group Stock Down 9.3%

The company has a market capitalization of $920.09 million, a PE ratio of -103.85 and a beta of 0.05. The company has a quick ratio of 2.07, a current ratio of 2.79 and a debt-to-equity ratio of 0.38. The firm has a 50-day moving average of $12.87 and a two-hundred day moving average of $10.73.

Pharming Group (NASDAQ:PHAR - Get Free Report) last issued its quarterly earnings data on Thursday, July 31st. The company reported $0.06 earnings per share for the quarter, topping the consensus estimate of ($0.10) by $0.16. The company had revenue of $93.20 million during the quarter, compared to analyst estimates of $70.36 million. Pharming Group had a negative return on equity of 3.31% and a negative net margin of 2.19%. Pharming Group has set its FY 2025 guidance at EPS. Equities research analysts predict that Pharming Group N.V. Sponsored ADR will post -0.2 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Pharming Group stock. EverSource Wealth Advisors LLC acquired a new stake in Pharming Group N.V. Sponsored ADR (NASDAQ:PHAR - Free Report) during the 2nd quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm acquired 2,979 shares of the company's stock, valued at approximately $32,000. Hedge funds and other institutional investors own 0.03% of the company's stock.

About Pharming Group

Pharming Group N.V., a biopharmaceutical company, develops and commercializes protein replacement therapies and precision medicines for the treatment of rare diseases in the United States, Europe, and internationally. The company offers RUCONEST, a recombinant C1 esterase inhibitor for the treatment of acute attacks in adult and adolescent patients with acute hereditary angioedema (HAE); and Joenja (leniolisib), an oral small molecule PI3K? inhibitor for the treatment of activated phosphoinositide 3-kinase delta syndrome.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.